Yantai Maiberry International Biopharmaceutical Co., Ltd. (迈百瑞生物) provides clinical development services and supplies clinical samples to support new drug R&D. The company has participated in nearly 100 domestic and international new drug development projects and helped clients obtain more than 20 clinical trial approvals in China, the US, and Australia. Four clients have used clinical samples provided by Maiberry to initiate Phase I/II trials in the United States. Maiberry is headquartered in Yantai. Financially, the company completed a B round financing exceeding ¥500 million RMB in June 2020. Existing investor Guotou Chuangye increased its investment by acquiring secondary shares, while several A‑round investors also participated in the B round.

Total raised

$71M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2020